India denies price hikes to Sanofi, Novartis, Allergan; Lundbeck launches Selincro in U.K.;

@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma

 @EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce

> Lundbeck has launched Selincro, its drug for alcohol dependence, in the U.K. Story

> India's National Pharmaceutical Pricing Authority (NPPA) has denied price boosts to Sanofi ($SNY), Novartis ($NVS), and Allergan ($AGN) for some of their imported drugs. Story

> Cipla and three other Indian drug companies are being investigated for their parts in an alleged deal that gave them preferential treatment for drug contracts. Story

> Pain Therapeutics, said Pfizer ($PFE), is unsure if it wants to go forward with regulatory approval for the painkiller Remoxy. Report

> Ralph Neas, CEO of the Generic Pharmaceutical Association (GPhA), used a letter in The New York Times to take a swipe at state laws restricting biosimilars. Letter

Medical Device News

@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce

 @DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce

> CareFusion's revenue slips 2%. Item

> U.K. pair challenges earlier finding that substandard PIP breast implants were safe. Report

> Quest settles New York case over illegal hiring practices. Story

Biotech News

@FierceBiotech: Special report: Which Big Biotechs are hitting the gas pedal on R&D spending? Feature | Follow @FierceBiotech

@JohnCFierce: Looks like Takeda management maybe in for more changes.The numbers are awful. Report | Follow @JohnCFierce

@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce

> Eli Lilly jettisons cancer contender after another Phase III failure. Story

> Biotech VC firm Frazier Healthcare closes in on $300M fund. More

> Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup. News

And Finally... Federal authorities in Puerto Rico have arrested a Pfizer executive that they say sent sexually explicit photos to a 16-year-old boy. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.